Role of Oxytocin in Myocardial Infarction

The Impact of Oxytocin Administration on Short and Long Term Prognosis in Patients Undergoing ST Elevation Myocardial Infarction

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03001635

Enrollment

Registered

2016-12-23

Start date

2017-01-31

Completion date

Unknown

Last updated

2016-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Brief summary

60 patients admitted to this ICCU at the Sheba medical Center will be randomly divided in to 2 groups. one group will receive the conventional treatment while the second group will receive the conventional treatment plus oxytocin infusion for 48 hours. all participants will undergo echo and cMRI during hospitalization.

Interventions

DRUGOxytocin

26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.

DRUGPlacebos

26 patients will receive 0.9% normal saline infusion for 6h as placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* age \> 18 years * current diagnosis of ST elevation myocardial infarction * no previous episodes of acute coronary syndrome * agreed to enter research

Exclusion criteria

* age \< 18 years * congestive heart failure (acute or chronic) * cardiomyopathy * life threatening arrhythmia at presentation * previous LV dysfunction * hypotension (systolic \< 100mmHg, diastolic\<50mmHg, 15% less than patients normal values) * tachycardia - pulse \> 100bpm * bradycardia - pulse \< 55 ppm * killip 3 or 4 at presentation * current use of nitrates * pregnancy * females - history of pathological GU bleeding * inability to give consent

Design outcomes

Primary

Measure	Time frame	Description
final infarction size	1 week	all patients will undergo an cMRI after 7 days

Secondary

Measure	Time frame	Description
Ejection fraction	48 hours	all patients will undergo echocardiography exam during the first 48 hours

Other

Measure	Time frame	Description
number on events with ventricular arrythmia	48 hours	all patients will be continually monitored for ventricular arrhythmia

Contacts

Primary ContactAnat Berkovitch, resident

anatberko@gmail.com972545746277

Backup ContactShlomi matetzky, Head of ICCU

Shlomi.Matetzky@sheba.health.gov.il972526667122

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026